Australia markets closed
  • ALL ORDS

    7,581.10
    -109.60 (-1.43%)
     
  • AUD/USD

    0.7259
    -0.0029 (-0.40%)
     
  • ASX 200

    7,275.60
    -108.60 (-1.47%)
     
  • OIL

    76.31
    +0.86 (+1.14%)
     
  • GOLD

    1,739.60
    -12.40 (-0.71%)
     
  • BTC-AUD

    57,879.52
    -2,604.32 (-4.31%)
     
  • CMC Crypto 200

    1,042.65
    -58.87 (-5.34%)
     

Equillium to Present at the BTIG Virtual Biotechnology Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LA JOLLA, Calif., August 05, 2021--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021.

Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas, M.D., Equillium’s executive vice president of research and development and chief medical officer, will provide a high-level overview of the Company’s clinical focus before engaging in a Fireside Chat with BTIG equity research analyst Justin Zelin.

Date:

Tuesday, August 10, 2021

Time:

12:00 PM Eastern Time | 9:00 AM Pacific Time

Location:

Virtual Webcast

BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005312/en/

Contacts

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting